These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 27091215)

  • 1. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
    Vijayakumar D; Jankovic J
    Drugs; 2016 May; 76(7):759-77. PubMed ID: 27091215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.
    Vijayakumar D; Jankovic J
    Drugs; 2016 May; 76(7):779-87. PubMed ID: 27091214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating and preventing levodopa-induced dyskinesias: current and future strategies.
    Durif F
    Drugs Aging; 1999 May; 14(5):337-45. PubMed ID: 10408734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
    Tran TN; Vo TNN; Frei K; Truong DD
    J Neural Transm (Vienna); 2018 Aug; 125(8):1109-1117. PubMed ID: 29971495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of levodopa-induced dyskinesias.
    Fahn S
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
    Krack P; Pollak P; Limousin P; Benazzouz A; Deuschl G; Benabid AL
    Brain; 1999 Jun; 122 ( Pt 6)():1133-46. PubMed ID: 10356065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
    Pilleri M; Antonini A
    Expert Opin Drug Saf; 2015 Feb; 14(2):281-94. PubMed ID: 25483147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced dyskinesias.
    Fabbrini G; Brotchie JM; Grandas F; Nomoto M; Goetz CG
    Mov Disord; 2007 Jul; 22(10):1379-1389. PubMed ID: 17427940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medical treatment of dyskinesia].
    Nishina K; Mizusawa H
    Nihon Rinsho; 2004 Sep; 62(9):1711-5. PubMed ID: 15462389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment and future prospects of dopa-induced dyskinesias.
    Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
    Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life.
    Manson A; Stirpe P; Schrag A
    J Parkinsons Dis; 2012; 2(3):189-98. PubMed ID: 23938226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amantadine Extended-Release (GOCOVRI
    Paik J; Keam SJ
    CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
    Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P; Konitsiotis S; Antonini A
    Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyskinesias and the subthalamic nucleus.
    Benabid AL; Benazzouz A; Limousin P; Koudsie A; Krack P; Piallat B; Pollak P
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S189-92. PubMed ID: 10762147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.